"The contract is a cost-plus monthly reimbursement arrangement. PolyNovo will continue to contribute to the trial through the provision of product, employee resources and infrastructure support." so, the way I read it, they are incurring a small loss on products supplied to BARDA. Well worth it in the long run assuming it's a success though.
Ann: BARDA increases funding US$10M, page-62
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.65 |
Change
0.090(3.52%) |
Mkt cap ! $1.830B | |||
| Open | High | Low | Value | Volume |
| $2.57 | $2.67 | $2.56 | $6.278M | 2.389M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 495 | $2.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.65 | 35370 | 3 |
View Market Depth
| Last trade - 16.10pm 26/09/2024 (20 minute delay) ? |
| PNV (ASX) Chart |